19S Subunit Suppressed Cells (IMAGE)
Caption
Figure on the left:
Analyzing the relative sensitivity of hundreds of cancer cell lines to commonly used anti-cancer drugs (each dot) reveals that cells with suppressed expression of one proteasome cap subunit are specifically resistant to treatments with the proteasome inhibitors MG132 and bortezomib. At the same time, their genetic profile makes them vulnerable to treatment with the pro-apoptotic drug ABT-263 (navitoclax).
Figure on the right:
Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.
Credit
Peter Tsvetkov
Usage Restrictions
None
License
Licensed content